Getting started

Supporting patients for a strong start to their treatment journey

~3 to 5 minute administration with subcutaneous formulation1

With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for approved indications, you can help patients start their journey with a treatment that not only demonstrated efficacy consistent with DARZALEX® (daratumumab) for approved indications, but offers the benefit of substantially faster administration time.1,2

The benefits of subcutaneous administration with DARZALEX FASPRO® include1,2:

~3 to 5 minute administration by a healthcare provider

Fixed dose; no weight-based calculations

Ready-to-use, single-dose vial, no dilution needed

Same dosing schedules as DARZALEX® for approved indications*

*Split first dose option for DARZALEX® is not applicable to DARZALEX FASPRO®.

Formulated with hyaluronidase for subcutaneous administration

DARZALEX FASPRO® is a CD38-targeted monoclonal antibody in a subcutaneous formulation1

  • DARZALEX FASPRO® contains recombinant hyaluronidase, which is a substance that increases permeability of subcutaneous tissue1
  • This makes it possible for administration to be completed in approximately 3 to 5 minutes1

DARZALEX FASPRO® contains recombinant hyaluronidase1

When injected, recombinant hyaluronidase increases permeability of subcutaneous tissue1

Enabling administration of DARZALEX FASPRO® in ~3 to 5 minutes1

Learn more about how daratumumab and hyaluronidase work in the body. Watch video

Find support resources to help patients get started on DARZALEX FASPRO®